ProJenX is a biotechnology company in the clinical stage, specializing in the development of groundbreaking, brain-penetrant, targeted therapies aimed at addressing neurodegenerative diseases, particularly with an initial emphasis on ALS. The formation of ProJenX originated from an extensive research partnership between Project ALS and scientists at Columbia University. This collaboration is dedicated to the swift development ...
ProJenX is a biotechnology company in the clinical stage, specializing in the development of groundbreaking, brain-penetrant, targeted therapies aimed at addressing neurodegenerative diseases, particularly with an initial emphasis on ALS. The formation of ProJenX originated from an extensive research partnership between Project ALS and scientists at Columbia University. This collaboration is dedicated to the swift development and commercialization of their primary therapeutic candidate, prosetin, designed to benefit individuals affected by ALS.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.